Pharmacotherapy for liposarcoma: current and emerging synthetic treatments.
Loading...
Embargo End Date
ICR Authors
Authors
Chamberlain, F
Benson, C
Thway, K
Huang, P
Jones, RL
Gennatas, S
Benson, C
Thway, K
Huang, P
Jones, RL
Gennatas, S
Document Type
Journal Article
Date
2021-04-21
Date Accepted
2021-03-18
Abstract
Liposarcomas are rare tumors arising from adipocytic tissue and accounting for approximately 15-20% of all soft tissue sarcomas. Liposarcoma can be further classified into histopathological subtypes with variable chemosensitivity according to subtype. Decisions regarding management should be made on an individual basis, but surgery for localized disease and systemic chemotherapy remain the mainstay of treatment. Currently, only doxorubicin and trabectedin have robust Phase III data to support their use in the management of advanced liposarcoma. However, in the subgroup analysis of a Phase III trial comparing eribulin with dacarbazine, there was a greater than 7-month improvement in median overall survival in those treated with eribulin. There are also promising results from emerging studies in novel and targeted agents for the treatment of liposarcoma.
Citation
Future oncology (London, England), 2021
Source Title
Publisher
TAYLOR & FRANCIS LTD
ISSN
1479-6694
eISSN
1744-8301
Collections
Research Team
Sarcoma Clinical Trials (R Jones)
Molecular and Systems Oncology
Sarcoma Clinical Trials (R Jones)
Molecular and Systems Oncology
Molecular and Systems Oncology
Sarcoma Clinical Trials (R Jones)
Molecular and Systems Oncology